= 0 1 0 1 O
< 1 2 1 2 O
2 3 4 3 4 B-upper_bound
prior 5 10 5 10 B-treatment
cytotoxic 11 20 11 20 I-treatment
chemotherapy 21 33 21 33 I-treatment
regimen 34 41 34 41 I-treatment

> 0 1 42 43 O
= 1 2 43 44 O
45 3 5 45 47 B-lower_bound
ml 6 8 48 50 I-lower_bound
/ 8 9 50 51 I-lower_bound
min/1.73 9 17 51 59 I-lower_bound
m^2 18 21 60 63 I-lower_bound
for 22 25 64 67 O
patients 26 34 68 76 O
receiving 35 44 77 86 O
pemetrexed 45 55 87 97 B-treatment

> 0 1 98 99 O
= 1 2 99 100 O
45 3 5 101 103 B-lower_bound
years 6 11 104 109 I-lower_bound
of 12 14 110 112 O
age 15 18 113 116 B-age
and 19 22 117 120 O
has 23 26 121 124 O
not 27 30 125 128 O
had 31 34 129 132 O
menses 35 41 133 139 O
for 42 45 140 143 O
> 46 47 144 145 O
= 47 48 145 146 O
2 49 50 147 148 O
years 51 56 149 154 O
, 56 57 154 155 O
amenorrheic 58 69 156 167 B-clinical_variable
for 70 73 168 171 O
< 74 75 172 173 O
2 76 77 174 175 O
years 78 83 176 181 O
without 84 91 182 189 O
hysterectomy 92 104 190 202 B-treatment
and 105 108 203 206 O
oophorectomy 109 121 207 219 B-treatment
and 122 125 220 223 O
a 126 127 224 225 O
follicle 128 136 226 234 O
- 136 137 234 235 O
stimulating 137 148 235 246 O
hormone 149 156 247 254 O
value 157 162 255 260 O
in 163 165 261 263 O
the 166 169 264 267 O
postmenopausal 170 184 268 282 O
range 185 190 283 288 O
upon 191 195 289 293 O
pretrial 196 204 294 302 O
( 205 206 303 304 O
screening 206 215 304 313 O
) 215 216 313 314 O
evaluation 217 227 315 325 O
, 227 228 325 326 O
or 229 231 327 329 O
post 232 236 330 334 B-treatment
hysterectomy 237 249 335 347 I-treatment
, 249 250 347 348 O
oophorectomy 251 263 349 361 O
or 264 266 362 364 O
tubal 267 272 365 370 B-treatment
ligation 273 281 371 379 I-treatment

Absolute 0 8 380 388 B-clinical_variable
neutrophil 9 19 389 399 I-clinical_variable
count 20 25 400 405 I-clinical_variable
> 26 27 406 407 O
= 27 28 407 408 O
1,500 29 34 409 414 B-lower_bound
/ 34 35 414 415 I-lower_bound
uL 35 37 415 417 I-lower_bound

Arm 0 3 418 421 O
A 4 5 422 423 O
dose 6 10 424 428 O
level 11 16 429 434 O
4 17 18 435 436 O
( 19 20 437 438 O
75 20 22 438 440 O
mg 23 25 441 443 O
/ 25 26 443 444 O
m^2 26 29 444 447 O
cisplatin 30 39 448 457 B-treatment
) 39 40 457 458 O

Arm 0 3 459 462 O
B 4 5 463 464 O
( 6 7 465 466 O
first 7 12 466 471 O
stage 13 18 472 477 O
of 19 21 478 480 O
phase 22 27 481 486 O
II 28 30 487 489 O
of 31 33 490 492 O
TRC102 34 40 493 499 B-treatment
and 41 44 500 503 O
pemetrexed 45 55 504 514 B-treatment

Eastern 0 7 515 522 B-clinical_variable
Cooperative 8 19 523 534 I-clinical_variable
Oncology 20 28 535 543 I-clinical_variable
Group 29 34 544 549 I-clinical_variable
( 35 36 550 551 I-clinical_variable
ECOG 36 40 551 555 I-clinical_variable
) 40 41 555 556 I-clinical_variable
performance 42 53 557 568 I-clinical_variable
status 54 60 569 575 I-clinical_variable
0 61 62 576 577 B-lower_bound
-1 63 65 578 580 O
( 66 67 581 582 O
Karnofsky 67 76 582 591 B-clinical_variable
> 77 78 592 593 O
= 78 79 593 594 O
70 80 82 595 597 B-lower_bound
% 82 83 597 598 I-lower_bound
) 83 84 598 599 O

For 0 3 600 603 O
patients 4 12 604 612 O
enrolled 13 21 613 621 O
in 22 24 622 624 O
Arm 25 28 625 628 O
B 29 30 629 630 O
( 31 32 631 632 O
first 32 37 632 637 O
stage 38 43 638 643 O
of 44 46 644 646 O
phase 47 52 647 652 O
II 53 55 653 655 O
of 56 58 656 658 O
TRC102 59 65 659 665 O
and 66 69 666 669 O
pemetrexed 70 80 670 680 O
) 80 81 680 681 O
measurable 82 92 682 692 O
disease 93 100 693 700 O
is 101 103 701 703 O
required 104 112 704 712 O
according 113 122 713 722 O
to 123 125 723 725 O
the 126 129 726 729 O
Response 130 138 730 738 O
Evaluation 139 149 739 749 O
Criteria 150 158 750 758 O
in 159 161 759 761 O
Solid 162 167 762 767 O
Tumors 168 174 768 774 O
( 175 176 775 776 O
RECIST 176 182 776 782 O
) 182 183 782 783 O
criteria 184 192 784 792 O
for 193 196 793 796 O
patients 197 205 797 805 O
with 206 210 806 810 O
solid 211 216 811 816 B-cancer
tumors 217 223 817 823 I-cancer
and 224 227 824 827 O
modified 228 236 828 836 O
RECIST 237 243 837 843 O
criteria 244 252 844 852 O
as 253 255 853 855 O
described 256 265 856 865 O
by 266 268 866 868 O
Byrne 269 274 869 874 O
and 275 278 875 878 O
Novak 279 284 879 884 O
for 285 288 885 888 O
patients 289 297 889 897 O
with 298 302 898 902 O
malignant 303 312 903 912 B-cancer
pleural 313 320 913 920 I-cancer
mesothelioma 321 333 921 933 I-cancer

Hemoglobin 0 10 934 944 B-clinical_variable
> 11 12 945 946 O
= 12 13 946 947 O
10.0 14 18 948 952 B-lower_bound
g 19 20 953 954 I-lower_bound
/ 20 21 954 955 I-lower_bound
dl 21 23 955 957 I-lower_bound

History 0 7 958 965 O
of 8 10 966 968 O
allergic 11 19 969 977 O
reactions 20 29 978 987 O
attributed 30 40 988 998 O
to 41 43 999 1001 O
compounds 44 53 1002 1011 O
of 54 56 1012 1014 O
similar 57 64 1015 1022 O
chemical 65 73 1023 1031 O
or 74 76 1032 1034 O
biologic 77 85 1035 1043 O
composition 86 97 1044 1055 O
to 98 100 1056 1058 O
TRC102 101 107 1059 1065 B-allergy_name
or 108 110 1066 1068 O
pemetrexed 111 121 1069 1079 B-allergy_name
and 122 125 1080 1083 O
cisplatin 126 135 1084 1093 B-allergy_name

Human 0 5 1094 1099 B-chronic_disease
immunodeficiency 6 22 1100 1116 I-chronic_disease
virus 23 28 1117 1122 I-chronic_disease
( 29 30 1123 1124 I-chronic_disease
HIV)-positive 30 43 1124 1137 I-chronic_disease
patients 44 52 1138 1146 O
on 53 55 1147 1149 O
combination 56 67 1150 1161 B-treatment
antiretroviral 68 82 1162 1176 I-treatment
therapy 83 90 1177 1184 I-treatment
are 91 94 1185 1188 O
ineligible 95 105 1189 1199 O
because 106 113 1200 1207 O
of 114 116 1208 1210 O
the 117 120 1211 1214 O
potential 121 130 1215 1224 O
for 131 134 1225 1228 O
pharmacokinetic 135 150 1229 1244 B-chronic_disease
interactions 151 163 1245 1257 I-chronic_disease
with 164 168 1258 1262 O
TRC102 169 175 1263 1269 B-treatment

Life 0 4 1270 1274 B-clinical_variable
expectancy 5 15 1275 1285 I-clinical_variable
of 16 18 1286 1288 O
greater 19 26 1289 1296 O
than 27 31 1297 1301 O
3 32 33 1302 1303 B-lower_bound
months 34 40 1304 1310 I-lower_bound

No 0 2 1311 1313 O
studies 3 10 1314 1321 O
have 11 15 1322 1326 O
been 16 20 1327 1331 O
performed 21 30 1332 1341 O
to 31 33 1342 1344 O
assess 34 40 1345 1351 O
potential 41 50 1352 1361 O
metabolic 51 60 1362 1371 O
and 61 64 1372 1375 O
transport 65 74 1376 1385 O
interactions 75 87 1386 1398 O
of 88 90 1399 1401 O
TRC102 91 97 1402 1408 B-treatment

Patients 0 8 1409 1417 O
who 9 12 1418 1421 O
are 13 16 1422 1425 O
receiving 17 26 1426 1435 O
any 27 30 1436 1439 O
other 31 36 1440 1445 O
investigational 37 52 1446 1461 B-treatment
agents 53 59 1462 1468 I-treatment

Patients 0 8 1469 1477 O
who 9 12 1478 1481 O
have 13 17 1482 1486 O
had 18 21 1487 1490 O
chemotherapy 22 34 1491 1503 B-treatment
or 35 37 1504 1506 O
radiotherapy 38 50 1507 1519 B-treatment
within 51 57 1520 1526 O
4 58 59 1527 1528 B-upper_bound
weeks 60 65 1529 1534 I-upper_bound
( 66 67 1535 1536 O
6 67 68 1536 1537 B-upper_bound
weeks 69 74 1538 1543 I-upper_bound
for 75 78 1544 1547 O
nitrosoureas 79 91 1548 1560 B-treatment
or 92 94 1561 1563 O
mitomycin 95 104 1564 1573 B-treatment
C 105 106 1574 1575 I-treatment
) 106 107 1575 1576 O
prior 108 113 1577 1582 O
to 114 116 1583 1585 O
entering 117 125 1586 1594 O
the 126 129 1595 1598 O
study 130 135 1599 1604 O
or 136 138 1605 1607 O
those 139 144 1608 1613 O
who 145 148 1614 1617 O
have 149 153 1618 1622 O
not 154 157 1623 1626 O
recovered 158 167 1627 1636 O
from 168 172 1637 1641 O
adverse 173 180 1642 1649 O
events 181 187 1650 1656 O
due 188 191 1657 1660 O
to 192 194 1661 1663 O
agents 195 201 1664 1670 O
administered 202 214 1671 1683 O
more 215 219 1684 1688 O
than 220 224 1689 1693 O
4 225 226 1694 1695 B-lower_bound
weeks 227 232 1696 1701 I-lower_bound
earlier 233 240 1702 1709 I-lower_bound

Patients 0 8 1710 1718 O
with 9 13 1719 1723 O
a 14 15 1724 1725 O
prior 16 21 1726 1731 B-treatment
cumulative 22 32 1732 1742 I-treatment
cisplatin 33 42 1743 1752 I-treatment
dose 43 47 1753 1757 I-treatment
> 48 49 1758 1759 O
300 50 53 1760 1763 B-lower_bound
mg 54 56 1764 1766 I-lower_bound
/ 56 57 1766 1767 I-lower_bound
m^2 57 60 1767 1770 I-lower_bound
( 61 62 1771 1772 O
pertains 62 70 1772 1780 O
to 71 73 1781 1783 O
Arm 74 77 1784 1787 O
A 78 79 1788 1789 O
only 80 84 1790 1794 O
) 84 85 1794 1795 O

Patients 0 8 1796 1804 O
with 9 13 1805 1809 O
active 14 20 1810 1816 O
brain 21 26 1817 1822 B-cancer
metastases 27 37 1823 1833 I-cancer
or 38 40 1834 1836 O
carcinomatous 41 54 1837 1850 B-cancer
meningitis 55 65 1851 1861 I-cancer
are 66 69 1862 1865 O
excluded 70 78 1866 1874 O
from 79 83 1875 1879 O
this 84 88 1880 1884 O
clinical 89 97 1885 1893 O
trial 98 103 1894 1899 O

Patients 0 8 1900 1908 O
with 9 13 1909 1913 O
known 14 19 1914 1919 O
disorders 20 29 1920 1929 O
associated 30 40 1930 1940 O
with 41 45 1941 1945 O
hemolysis 46 55 1946 1955 B-chronic_disease

Patients 0 8 1956 1964 O
with 9 13 1965 1969 O
thromboembolic 14 28 1970 1984 B-chronic_disease
disease 29 36 1985 1992 I-chronic_disease
and 37 40 1993 1996 O
on 41 43 1997 1999 O
anticoagulation 44 59 2000 2015 B-treatment

Platelets 0 9 2016 2025 B-clinical_variable
> 10 11 2026 2027 O
= 11 12 2027 2028 O
100,000 13 20 2029 2036 B-lower_bound
/ 20 21 2036 2037 I-lower_bound
uL 21 23 2037 2039 I-lower_bound

Pregnant 0 8 2040 2048 B-pregnancy
women 9 14 2049 2054 B-gender
are 15 18 2055 2058 O
excluded 19 27 2059 2067 O
from 28 32 2068 2072 O
this 33 37 2073 2077 O
study 38 43 2078 2083 O
because 44 51 2084 2091 O
TRC102 52 58 2092 2098 B-treatment
is 59 61 2099 2101 O
agent 62 67 2102 2107 O
with 68 72 2108 2112 O
the 73 76 2113 2116 O
potential 77 86 2117 2126 O
for 87 90 2127 2130 O
teratogenic 91 102 2131 2142 O
or 103 105 2143 2145 O
abortifacient 106 119 2146 2159 O
effects 120 127 2160 2167 O

Prothrombin 0 11 2168 2179 B-clinical_variable
time 12 16 2180 2184 I-clinical_variable
or 17 19 2185 2187 O
international 20 33 2188 2201 B-clinical_variable
normalized 34 44 2202 2212 I-clinical_variable
ratio 45 50 2213 2218 I-clinical_variable
( 51 52 2219 2220 I-clinical_variable
INR 52 55 2220 2223 I-clinical_variable
) 55 56 2223 2224 I-clinical_variable
= 57 58 2225 2226 O
< 58 59 2226 2227 O
1.5 60 63 2228 2231 B-upper_bound
x 64 65 2232 2233 I-upper_bound
upper 66 71 2234 2239 I-upper_bound
limit 72 77 2240 2245 I-upper_bound
of 78 80 2246 2248 I-upper_bound
normal 81 87 2249 2255 I-upper_bound
( 88 89 2256 2257 I-upper_bound
ULN 89 92 2257 2260 I-upper_bound
) 92 93 2260 2261 I-upper_bound

Serum 0 5 2262 2267 B-clinical_variable
creatinine 6 16 2268 2278 I-clinical_variable
= 17 18 2279 2280 O
< 18 19 2280 2281 O
1.5 20 23 2282 2285 B-upper_bound
x 24 25 2286 2287 I-upper_bound
ULN 26 29 2288 2291 I-upper_bound

The 0 3 2292 2295 O
effects 4 11 2296 2303 O
of 12 14 2304 2306 O
TRC102 15 21 2307 2313 B-treatment
on 22 24 2314 2316 O
the 25 28 2317 2320 O
developing 29 39 2321 2331 O
human 40 45 2332 2337 O
fetus 46 51 2338 2343 O
are 52 55 2344 2347 O
unknown 56 63 2348 2355 O
; 63 64 2355 2356 O
for 65 68 2357 2360 O
this 69 73 2361 2365 O
reason 74 80 2366 2372 O
and 81 84 2373 2376 O
because 85 92 2377 2384 O
TRC102 93 99 2385 2391 O
as 100 102 2392 2394 O
well 103 107 2395 2399 O
as 108 110 2400 2402 O
other 111 116 2403 2408 O
therapeutic 117 128 2409 2420 B-treatment
agents 129 135 2421 2427 I-treatment
used 136 140 2428 2432 O
in 141 143 2433 2435 O
this 144 148 2436 2440 O
trial 149 154 2441 2446 O
are 155 158 2447 2450 O
known 159 164 2451 2456 O
to 165 167 2457 2459 O
be 168 170 2460 2462 O
teratogenic 171 182 2463 2474 O
, 182 183 2474 2475 O
women 184 189 2476 2481 B-gender
of 190 192 2482 2484 O
child 193 198 2485 2490 O
- 198 199 2490 2491 O
bearing 199 206 2491 2498 O
potential 207 216 2499 2508 O
and 217 220 2509 2512 O
men 221 224 2513 2516 O
must 225 229 2517 2521 O
agree 230 235 2522 2527 B-contraception_consent
to 236 238 2528 2530 I-contraception_consent
use 239 242 2531 2534 I-contraception_consent
adequate 243 251 2535 2543 I-contraception_consent
contraception 252 265 2544 2557 I-contraception_consent
( 266 267 2558 2559 O
hormonal 267 275 2559 2567 B-contraception_consent
or 276 278 2568 2570 I-contraception_consent
barrier 279 286 2571 2578 I-contraception_consent
method 287 293 2579 2585 I-contraception_consent
of 294 296 2586 2588 I-contraception_consent
birth 297 302 2589 2594 I-contraception_consent
control 303 310 2595 2602 I-contraception_consent
; 310 311 2602 2603 O
abstinence 312 322 2604 2614 B-contraception_consent
) 322 323 2614 2615 O
prior 324 329 2616 2621 O
to 330 332 2622 2624 O
study 333 338 2625 2630 O
entry 339 344 2631 2636 O
, 344 345 2636 2637 O
for 346 349 2638 2641 O
the 350 353 2642 2645 O
duration 354 362 2646 2654 O
of 363 365 2655 2657 O
study 366 371 2658 2663 O
participation 372 385 2664 2677 O
, 385 386 2677 2678 O
and 387 390 2679 2682 O
4 391 392 2683 2684 B-upper_bound
months 393 399 2685 2691 I-upper_bound
after 400 405 2692 2697 I-upper_bound
completion 406 416 2698 2708 O
of 417 419 2709 2711 O
the 420 423 2712 2715 O
study 424 429 2716 2721 B-treatment
drugs 430 435 2722 2727 I-treatment

Total 0 5 2728 2733 B-clinical_variable
bilirubin 6 15 2734 2743 I-clinical_variable
< 16 17 2744 2745 O
1.5 18 21 2746 2749 B-upper_bound
x 22 23 2750 2751 I-upper_bound
ULN 24 27 2752 2755 I-upper_bound

Uncontrolled 0 12 2756 2768 O
intercurrent 13 25 2769 2781 O
illness 26 33 2782 2789 O
including 34 43 2790 2799 O
, 43 44 2799 2800 O
but 45 48 2801 2804 O
not 49 52 2805 2808 O
limited 53 60 2809 2816 O
to 61 63 2817 2819 O
, 63 64 2819 2820 O
ongoing 65 72 2821 2828 O
or 73 75 2829 2831 O
active 76 82 2832 2838 B-chronic_disease
infection 83 92 2839 2848 I-chronic_disease
, 92 93 2848 2849 O
symptomatic 94 105 2850 2861 O
congestive 106 116 2862 2872 B-chronic_disease
heart 117 122 2873 2878 I-chronic_disease
failure 123 130 2879 2886 I-chronic_disease
, 130 131 2886 2887 O
unstable 132 140 2888 2896 B-chronic_disease
angina 141 147 2897 2903 I-chronic_disease
pectoris 148 156 2904 2912 I-chronic_disease
, 156 157 2912 2913 O
cardiac 158 165 2914 2921 B-chronic_disease
arrhythmia 166 176 2922 2932 I-chronic_disease
, 176 177 2932 2933 O
or 178 180 2934 2936 O
psychiatric 181 192 2937 2948 B-chronic_disease
illness 193 200 2949 2956 I-chronic_disease
/ 200 201 2956 2957 I-chronic_disease
social 201 207 2957 2963 I-chronic_disease
situations 208 218 2964 2974 I-chronic_disease
that 219 223 2975 2979 O
would 224 229 2980 2985 O
limit 230 235 2986 2991 O
compliance 236 246 2992 3002 O
with 247 251 3003 3007 O
study 252 257 3008 3013 O
requirements 258 270 3014 3026 O

a 0 1 3027 3028 O
calculated 2 12 3029 3039 O
creatinine 13 23 3040 3050 B-clinical_variable
clearance 24 33 3051 3060 I-clinical_variable
> 34 35 3061 3062 O
= 35 36 3062 3063 O
60 37 39 3064 3066 B-lower_bound
ml 40 42 3067 3069 I-lower_bound
/ 42 43 3069 3070 I-lower_bound
min/1.73 43 51 3070 3078 I-lower_bound
m^2 52 55 3079 3082 I-lower_bound
( 56 57 3083 3084 O
Cockcroft 57 66 3084 3093 B-clinical_variable
- 66 67 3093 3094 I-clinical_variable
Gault 67 72 3094 3099 I-clinical_variable
method 73 79 3100 3106 I-clinical_variable
) 79 80 3106 3107 O
for 81 84 3108 3111 O
patients 85 93 3112 3120 O
receiving 94 103 3121 3130 O
combination 104 115 3131 3142 O
of 116 118 3143 3145 O
cisplatin 119 128 3146 3155 B-treatment
and 129 132 3156 3159 O
pemetrexed 133 143 3160 3170 B-treatment

anti 0 4 3171 3175 B-treatment
- 4 5 3175 3176 I-treatment
seizure 5 12 3176 3183 I-treatment
medications 13 24 3184 3195 I-treatment
are 25 28 3196 3199 O
eligible 29 37 3200 3208 O
to 38 40 3209 3211 O
participate 41 52 3212 3223 O

documented 0 10 3224 3234 O
hysterectomy 11 23 3235 3247 B-treatment
or 24 26 3248 3250 O
oophorectomy 27 39 3251 3263 B-treatment
must 40 44 3264 3268 O
be 45 47 3269 3271 O
confirmed 48 57 3272 3281 O
with 58 62 3282 3286 O
medical 63 70 3287 3294 O
records 71 78 3295 3302 O
of 79 81 3303 3305 O
the 82 85 3306 3309 O
actual 86 92 3310 3316 O
procedure 93 102 3317 3326 O
or 103 105 3327 3329 O
confirmed 106 115 3330 3339 O
by 116 118 3340 3342 O
ultrasound 119 129 3343 3353 O
; 129 130 3353 3354 O
tubal 131 136 3355 3360 B-chronic_disease
ligation 137 145 3361 3369 I-chronic_disease
must 146 150 3370 3374 O
be 151 153 3375 3377 O
confirmed 154 163 3378 3387 O
with 164 168 3388 3392 O
medical 169 176 3393 3400 O
records 177 184 3401 3408 O
of 185 187 3409 3411 O
the 188 191 3412 3415 O
actual 192 198 3416 3422 O
procedure 199 208 3423 3432 O
otherwise 209 218 3433 3442 O
the 219 222 3443 3446 O
patient 223 230 3447 3454 O
must 231 235 3455 3459 O
be 236 238 3460 3462 O
willing 239 246 3463 3470 O
to 247 249 3471 3473 O
use 250 253 3474 3477 O
2 254 255 3478 3479 O
adequate 256 264 3480 3488 O
barrier 265 272 3489 3496 O
methods 273 280 3497 3504 O
throughout 281 291 3505 3515 O
the 292 295 3516 3519 O
study 296 301 3520 3525 O
, 301 302 3525 3526 O
starting 303 311 3527 3535 O
with 312 316 3536 3540 O
the 317 320 3541 3544 O
screening 321 330 3545 3554 O
visit 331 336 3555 3560 O
though 337 343 3561 3567 O
4 344 345 3568 3569 O
months 346 352 3570 3576 O
after 353 358 3577 3582 O
the 359 362 3583 3586 O
last 363 367 3587 3591 O
dose 368 372 3592 3596 O
of 373 375 3597 3599 O
study 376 381 3600 3605 B-treatment
drugs 382 387 3606 3611 I-treatment

for 0 3 3612 3615 O
whom 4 8 3616 3620 O
the 9 12 3621 3624 O
current 13 20 3625 3632 O
dose 21 25 3633 3637 O
level 26 31 3638 3643 O
of 32 34 3644 3646 O
cisplatin 35 44 3647 3656 B-treatment
in 45 47 3657 3659 O
combination 48 59 3660 3671 O
with 60 64 3672 3676 O
pemetrexed 65 75 3677 3687 O
is 76 78 3688 3690 O
appropriate 79 90 3691 3702 O

intervening 0 11 3703 3714 B-treatment
treatment 12 21 3715 3724 I-treatment
is 22 24 3725 3727 O
allowed 25 32 3728 3735 O

men 0 3 3736 3739 B-gender
treated 4 11 3740 3747 O
or 12 14 3748 3750 O
enrolled 15 23 3751 3759 O
on 24 26 3760 3762 O
this 27 31 3763 3767 O
protocol 32 40 3768 3776 O
must 41 45 3777 3781 O
also 46 50 3782 3786 O
agree 51 56 3787 3792 B-contraception_consent
to 57 59 3793 3795 I-contraception_consent
use 60 63 3796 3799 I-contraception_consent
adequate 64 72 3800 3808 I-contraception_consent
contraception 73 86 3809 3822 I-contraception_consent
prior 87 92 3823 3828 O
to 93 95 3829 3831 O
the 96 99 3832 3835 O
study 100 105 3836 3841 O
, 105 106 3841 3842 O
for 107 110 3843 3846 O
the 111 114 3847 3850 O
duration 115 123 3851 3859 O
of 124 126 3860 3862 O
study 127 132 3863 3868 O
participation 133 146 3869 3882 O
, 146 147 3882 3883 O
and 148 151 3884 3887 O
4 152 153 3888 3889 B-upper_bound
months 154 160 3890 3896 I-upper_bound
after 161 166 3897 3902 I-upper_bound
completion 167 177 3903 3913 O
of 178 180 3914 3916 O
TRC102 181 187 3917 3923 B-treatment
, 187 188 3923 3924 O
pemetrexed 189 199 3925 3935 B-treatment
and 200 203 3936 3939 O
cisplatin 204 213 3940 3949 B-treatment
administration 214 228 3950 3964 O
; 228 229 3964 3965 O
non 230 233 3966 3969 O
- 233 234 3969 3970 O
childbearing 234 246 3970 3982 O
potential 247 256 3983 3992 O
is 257 259 3993 3995 O
defined 260 267 3996 4003 O
as 268 270 4004 4006 O
( 271 272 4007 4008 O
by 272 274 4008 4010 O
other 275 280 4011 4016 O
than 281 285 4017 4021 O
medical 286 293 4022 4029 O
reasons 294 301 4030 4037 O

patients 0 8 4038 4046 O
who 9 12 4047 4050 O
have 13 17 4051 4055 O
had 18 21 4056 4059 O
targeted 22 30 4060 4068 B-treatment
therapy 31 38 4069 4076 I-treatment
will 39 43 4077 4081 O
be 44 46 4082 4084 O
required 47 55 4085 4093 O
to 56 58 4094 4096 O
wait 59 63 4097 4101 O
2 64 65 4102 4103 B-upper_bound
weeks 66 71 4104 4109 I-upper_bound
due 72 75 4110 4113 O
to 76 78 4114 4116 O
short 79 84 4117 4122 O
half 85 89 4123 4127 O
- 89 90 4127 4128 O
life 90 94 4128 4132 O
of 95 97 4133 4135 O
the 98 101 4136 4139 O
drugs 102 107 4140 4145 O
; 107 108 4145 4146 O
treatment 109 118 4147 4156 B-treatment
with 119 123 4157 4161 I-treatment
bisphosphonates 124 139 4162 4177 I-treatment
is 140 142 4178 4180 O
permitted 143 152 4181 4190 O

patients 0 8 4191 4199 O
with 9 13 4200 4204 O
histologically 14 28 4205 4219 O
or 29 31 4220 4222 O
cytologically 32 45 4223 4236 O
proven 46 52 4237 4243 O
advanced 53 61 4244 4252 O
solid 62 67 4253 4258 B-cancer
tumors 68 74 4259 4265 I-cancer
for 75 78 4266 4269 O
which 79 84 4270 4275 O
standard 85 93 4276 4284 B-treatment
treatments 94 104 4285 4295 I-treatment
are 105 108 4296 4299 O
not 109 112 4300 4303 O
available 113 122 4304 4313 O

patients 0 8 4314 4322 O
with 9 13 4323 4327 O
histologically 14 28 4328 4342 O
proven 29 35 4343 4349 O
chemotherapy 36 48 4350 4362 B-treatment
- 48 49 4362 4363 O
naive 49 54 4363 4368 O
advanced 55 63 4369 4377 O
unresectable 64 76 4378 4390 O
solid 77 82 4391 4396 B-cancer
tumors 83 89 4397 4403 I-cancer
for 90 93 4404 4407 O
which 94 99 4408 4413 O
pemetrexed 100 110 4414 4424 B-treatment
combined 111 119 4425 4433 I-treatment
with 120 124 4434 4438 I-treatment
cisplatin 125 134 4439 4448 I-treatment
is 135 137 4449 4451 O
an 138 140 4452 4454 O
indicated 141 150 4455 4464 O
regimen 151 158 4465 4472 O

patients 0 8 4473 4481 O
with 9 13 4482 4486 O
malignant 14 23 4487 4496 O
pleural 24 31 4497 4504 B-cancer
or 32 34 4505 4507 O
peritoneal 35 45 4508 4518 B-cancer
mesothelioma 46 58 4519 4531 I-cancer
who 59 62 4532 4535 O
had 63 66 4536 4539 O
progressed 67 77 4540 4550 O
while 78 83 4551 4556 O
being 84 89 4557 4562 O
treated 90 97 4563 4570 O
with 98 102 4571 4575 O
or 103 105 4576 4578 O
had 106 109 4579 4582 O
recurred 110 118 4583 4591 O

patients 0 8 4592 4600 O
with 9 13 4601 4605 O
treated 14 21 4606 4613 O
brain 22 27 4614 4619 B-cancer
metastases 28 38 4620 4630 I-cancer
, 38 39 4630 4631 O
whose 40 45 4632 4637 O
brain 46 51 4638 4643 B-cancer
metastatic 52 62 4644 4654 I-cancer
disease 63 70 4655 4662 I-cancer
has 71 74 4663 4666 O
remained 75 83 4667 4675 O
stable 84 90 4676 4682 O
for 91 94 4683 4686 O
greater 95 102 4687 4694 O
than 103 107 4695 4699 O
or 108 110 4700 4702 O
equal 111 116 4703 4708 O
to 117 119 4709 4711 O
4 120 121 4712 4713 B-lower_bound
weeks 122 127 4714 4719 I-lower_bound
without 128 135 4720 4727 O
requiring 136 145 4728 4737 O
steroid 146 153 4738 4745 B-treatment

pleural 0 7 4746 4753 B-chronic_disease
effusion 8 16 4754 4762 I-chronic_disease
and 17 20 4763 4766 O
ascites 21 28 4767 4774 B-chronic_disease
are 29 32 4775 4778 O
not 33 36 4779 4782 O
considered 37 47 4783 4793 O
measurable 48 58 4794 4804 O
disease 59 66 4805 4812 O

should 0 6 4813 4819 O
a 7 8 4820 4821 O
woman 9 14 4822 4827 B-gender
become 15 21 4828 4834 B-pregnancy
pregnant 22 30 4835 4843 I-pregnancy
or 31 33 4844 4846 O
suspect 34 41 4847 4854 O
she 42 45 4855 4858 O
is 46 48 4859 4861 B-pregnancy
pregnant 49 57 4862 4870 I-pregnancy
while 58 63 4871 4876 O
she 64 67 4877 4880 O
or 68 70 4881 4883 O
her 71 74 4884 4887 O
partner 75 82 4888 4895 O
is 83 85 4896 4898 O
participating 86 99 4899 4912 O
in 100 102 4913 4915 O
this 103 107 4916 4920 O
study 108 113 4921 4926 O
, 113 114 4926 4927 O
she 115 118 4928 4931 O
should 119 125 4932 4938 O
inform 126 132 4939 4945 O
her 133 136 4946 4949 O
treating 137 145 4950 4958 O
physician 146 155 4959 4968 O
immediately 156 167 4969 4980 O

within 0 6 4981 4987 O
6 7 8 4988 4989 B-upper_bound
months 9 15 4990 4996 I-upper_bound
of 16 18 4997 4999 O
being 19 24 5000 5005 O
treated 25 32 5006 5013 B-treatment
with 33 37 5014 5018 I-treatment
pemetrexed 38 48 5019 5029 I-treatment
and 49 52 5030 5033 I-treatment
cisplatin 53 62 5034 5043 I-treatment
or 63 65 5044 5046 I-treatment
carboplatin 66 77 5047 5058 I-treatment
frontline 78 87 5059 5068 I-treatment

